Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis.
作者信息
Uno H, Claggett B, Tian L, Fu H, Huang B, Kim D H, Wei L J
机构信息
Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston.
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston.
出版信息
Ann Oncol. 2018 May 1;29(5):1092-1094. doi: 10.1093/annonc/mdy109.
Abstract
摘要
相似文献
1
Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis.在生存分析工具库中添加一种具有临床解读功能的新分析方法。
Ann Oncol. 2018 May 1;29(5):1092-1094. doi: 10.1093/annonc/mdy109.
2
[Analytical epidemiology of stomach cancer].[胃癌的分析性流行病学]
Vopr Onkol. 2013;59(5):565-70.
3
Survival analysis part IV: further concepts and methods in survival analysis.生存分析第四部分：生存分析中的进一步概念与方法。
Br J Cancer. 2003 Sep 1;89(5):781-6. doi: 10.1038/sj.bjc.6601117.
4
Interpretation of population-based cancer survival data.基于人群的癌症生存数据解读。
IARC Sci Publ. 1998(145):13-7.
5
[Establishing criteria for survival of oncology patients on a regional level].[制定区域层面肿瘤患者生存标准]
Vopr Onkol. 2000;46(2):149-52.
6
On estimation in relative survival.关于相对生存的估计
Biometrics. 2012 Mar;68(1):113-20. doi: 10.1111/j.1541-0420.2011.01640.x. Epub 2011 Jun 20.
7
Immortal person-time in studies of cancer outcomes.癌症结局研究中的不朽人时。
J Clin Oncol. 2009 Aug 10;27(23):e55-6. doi: 10.1200/JCO.2009.24.1877. Epub 2009 Jul 13.
8
Stopping when the experimental regimen does not appear to help.当实验方案似乎没有帮助时停止。
Stat Med. 1994;13(13-14):1453-8. doi: 10.1002/sim.4780131321.
9
Parametric versus non-parametric methods for estimating cure rates based on censored survival data.基于删失生存数据估计治愈率的参数法与非参数法
Stat Med. 1994 May 15;13(9):983-6. doi: 10.1002/sim.4780130908.
10
Survival of women with locally advanced breast cancer at a teaching hospital in Lahore.拉合尔一家教学医院中局部晚期乳腺癌女性患者的生存率
J Pak Med Assoc. 2010 Dec;60(12):1067-8; author reply 1068-9.
引用本文的文献
1
A Critical Analysis of All-Cause Deaths during COVID-19 Vaccination in an Italian Province.意大利某省新冠疫苗接种期间全因死亡情况的批判性分析
Microorganisms. 2024 Jun 30;12(7):1343. doi: 10.3390/microorganisms12071343.
2
Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study.香港 COVID-19 疫苗接种和 SARS-CoV-2 感染后糖尿病的发病率：一项基于人群的队列研究。
PLoS Med. 2023 Jul 24;20(7):e1004274. doi: 10.1371/journal.pmed.1004274. eCollection 2023 Jul.
3
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials.接受醋酸阿比特龙治疗的转移性前列腺癌患者同时使用质子泵抑制剂与生存率之间的关联：来自三项随机对照试验的汇总数据的事后分析
Prostate Cancer Prostatic Dis. 2024 Sep;27(3):444-450. doi: 10.1038/s41391-023-00695-x. Epub 2023 Jul 18.
4
Implications of Pleural Fluid Composition in Persistent Pleural Effusion following Orthotopic Liver Transplant.原位肝移植后持续性胸腔积液中胸腔液成分的意义。
Med Sci (Basel). 2023 Mar 17;11(1):24. doi: 10.3390/medsci11010024.
5
Comparison of two diagnostic intervention packages for community-based active case finding for tuberculosis: an open-label randomized controlled trial.两种用于社区肺结核主动病例发现的诊断干预方案的比较：一项开放标签随机对照试验。
Nat Med. 2023 Apr;29(4):1009-1016. doi: 10.1038/s41591-023-02247-1. Epub 2023 Mar 9.
6
Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib.抗生素治疗与接受索拉非尼治疗的肝细胞癌患者较差的预后相关。
J Hepatocell Carcinoma. 2021 Nov 30;8:1485-1493. doi: 10.2147/JHC.S317957. eCollection 2021.
7
Restricted mean survival time versus conventional measures for treatment decision-making.限制平均生存时间与常规措施在治疗决策中的比较。
J Am Geriatr Soc. 2021 Aug;69(8):2282-2289. doi: 10.1111/jgs.17195. Epub 2021 Apr 26.
8
Time spent outside of the hospital, CKD progression, and mortality: a prospective cohort study.院外时间、慢性肾脏病进展和死亡率：一项前瞻性队列研究。
Int Urol Nephrol. 2021 Aug;53(8):1659-1663. doi: 10.1007/s11255-020-02749-8. Epub 2021 Jan 1.
9
An alternative approach for estimating the number needed to treat for survival endpoints.一种用于估计生存终点所需治疗人数的替代方法。
PLoS One. 2019 Oct 18;14(10):e0223301. doi: 10.1371/journal.pone.0223301. eCollection 2019.
10
Home Time as a Patient-Centered Outcome in Administrative Claims Data.家庭时间作为行政索赔数据中的以患者为中心的结果。
J Am Geriatr Soc. 2019 Feb;67(2):347-351. doi: 10.1111/jgs.15705. Epub 2018 Dec 21.
本文引用的文献
1
Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.免疫检查点抑制剂治疗癌症的临床试验中通过受限平均生存时间衡量的治疗效果。
Ann Oncol. 2018 May 1;29(5):1320-1324. doi: 10.1093/annonc/mdy075.
2
Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.通过受限平均生存时间进行两样本检验以分析事件时间观测值的效率
Biometrics. 2018 Jun;74(2):694-702. doi: 10.1111/biom.12770. Epub 2017 Sep 12.
3
Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?受限平均生存时间：癌症试验中事件发生时间分析的必要终点？
J Clin Oncol. 2016 Oct 1;34(28):3474-6. doi: 10.1200/JCO.2016.67.8045. Epub 2016 Aug 9.
4
The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.作为随机临床试验中治疗效益的一种以患者为中心的衡量指标，净生存机会。
JAMA Oncol. 2016 Jul 1;2(7):901-5. doi: 10.1001/jamaoncol.2015.6359.
5
Describing Differences in Survival Curves.描述生存曲线的差异。
JAMA Oncol. 2016 Jul 1;2(7):906-7. doi: 10.1001/jamaoncol.2016.0001.
6
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
7
Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.非劣效性研究中用于比较治疗效果或安全性的风险比替代方法。
Ann Intern Med. 2015 Jul 21;163(2):127-34. doi: 10.7326/M14-1741.
8
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.超越风险比：在生存分析中量化组间差异。
J Clin Oncol. 2014 Aug 1;32(22):2380-5. doi: 10.1200/JCO.2014.55.2208. Epub 2014 Jun 30.
9
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.限制平均生存时间：替代风险比的方法，用于设计和分析具有时间事件结局的随机试验。
BMC Med Res Methodol. 2013 Dec 7;13:152. doi: 10.1186/1471-2288-13-152.
10
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.增强型生存数据分析：从已发表的 Kaplan-Meier 生存曲线中重建数据。
BMC Med Res Methodol. 2012 Feb 1;12:9. doi: 10.1186/1471-2288-12-9.
Zotero 插件